인쇄하기
취소

KPDS, “The MFDS’s measure on olmesartan is inadequate”

Published: 2016-06-07 14:00:02
Updated: 2016-06-07 14:00:02

The prescription policy for olmesartan, a hypertensive treatment, has been re-discussed.

On the 2nd, the Korean Pharmacists for Democratic Society(hereinafter referring to KPDS) emphasized necessity to tighten the prescription policy, as arguing the Ministry of Food and Drug Safety’s(MFDS) change of approval articles on olmesartan was inadequate.

When it came to the antihypertensive olmesar...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.